The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

Clinical Infectious Diseases

Volumn 41, Issue 5 SUPPL., 2005, Pages

  Ellis Grosse, E J ^a   Babinchak, T ^a   Dartois, N ^b   Rose, G ^a   Loh, E ^a  

^a PFIZER INC   (United States)

^b Wyeth   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AZTREONAM; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; FEVER; FOLLICULITIS; FURUNCULOSIS; HEADACHE; HOSPITALIZATION; HUMAN; HYPERTENSION; INSOMNIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NONHUMAN; PAIN; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; REVIEW; SKIN ABSCESS; SKIN APPENDAGE DISEASE; SKIN INFECTION; SKIN TOXICITY; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VOMITING;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZTREONAM; BACTERIA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; RANDOM ALLOCATION; SKIN DISEASES, BACTERIAL; VANCOMYCIN;

EID: 23844479577     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/431675     Document Type: Review

References (37)

1. Deery HG 2nd. Outpatient parenteral anti-infective therapy for skin and soft-tissue infections. Infect Dis Clin North Am 1998; 12:935-49.
2. Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis 2001;33(Suppl 2):S84-93.
3. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999; 44:19-23.
4. Doern GV, Jones RN, Pfaller MA, Kugler KC, Beach ML. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). SENTRY study group (North America). Diagn Microbiol Infect Dis 1999; 34:65-72.
5. Summanen PH, Talan DA, Strong C, et al. Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin Infect Dis 1995;20(Suppl 2):S279-82.
6. Boyce JM. Methicillin-resistant Staphylococcus aureus in hospitals and long-term care facilities: microbiology, epidemiology, and preventive measures. Infect Control Hosp Epidemiol 1992; 13:725-37.
7. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976-84.
8. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6: 428-42.
9. Falagas ME, Barefoot L, Griffith J, Ruthazar R, Snydman DR. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996; 15: 913-21.
10. Shmuely H, Pitlik S, Drucker M, Samra Z, Konisberger H, Leibovici L. Prediction of mortality in patients with bacteremia: the importance of pre-existing renal insufficiency. Ren Fail 2000; 22:99-108.
11. Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:322-3.
12. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7:327-32.
13. Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 1999; 9:1459-62.
14. Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol 2001; 1:464-9.
15. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001; 40:173-7.
16. Hoellman DB, Pankuch GA, Jacobs MR, Appelbaum PC. Antipneumococcal activity of GAR 936, a new glycylcycline, compared to those of nine other agents against penicillin susceptible and resistant pneumococci. Antimicrob Agents Chemother 2000; 44:1085-8.
17. Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43:738-44.
18. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36:19-36.
19. Hedberg M, Nord CE. In vitro activity of anaerobic bacteria to GAR-936, a new glycylcycline [abstract 411]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999; 39:26.
20. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47:400-4.
21. Rennie RP, Jones RN, Mutnick AH. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003;45:287-93.
22. Rose G, Loh E. Efficacy and safety of tigecycline compared with vancomycin/aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial [abstract TH-13]. In: Program and abstracts of the 11th International Symposium on Staphylococci and Staphylococcal Infections (Charleston, SC). International Society on Staphylococci and Staphylococcal Infections, 2004.
23. Dartois N. Results of a phase 3, double-blind, safety and efficacy study comparing tigecycline with vancomycin/aztreonam to treat complicated skin and skin structure infections [abstract L-986]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
24. Vancocin HCI. Sterile vancomycin hydrochloride; intravenous. Physicians' desk reference, 55th ed. Montvale, NJ: MedicalEconomics, 2001.
25. NCCLS. Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard [NCCLS document M11-A5]. 5th ed. Wayne, PA: NCCLS, 2001.
26. NCCLS. Methods for dilution antimicrobial susceptibility tests for microbes that grow aerobically: approved standard. 6th ed. Wayne, PA: NCCLS, 2003.
27. NCCLS. Performance standards for antimicrobial disk susceptibility tests: approved standard. 8th ed. Wayne, PA: NCCLS, 2003.
28. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927; 22:209-12.
29. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26:404-13.
30. Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26:704-14.
31. Murray JA, Wilson S, Klein S, et al. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients. A phase 2, clinical trial [abstract]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Vol. 43. Washington, DC: American Society for Microbiology, 2003:416.
32. Dartois N, Gioud-Paquet M, Ellis-Grosse EJ, et al. Tigecycline vs imipenem/cilastatin for treatment of complicated intra-abdominal infections [abstract L-992c]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
33. Muralidharan G, Getsy J, Mayer P, et al. Pharmacokinetics (PK), safety, and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects [abstract]. In: Program and abstracts of the 39th Interscience Conference of Antimicrobial Agents and Chemotherapy (San Francisco). Vol. 39. Washington, DC: American Society for Microbiology, 1999:303.
34. Muralidharan G, Mojaverian P, Micalizzi M, et al. The effects of age and gender on the pharmacokinetics, safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects [abstract 502]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:17.
35. Sesoko S, Umemura K, Nakashima M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males [abstract 1761]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:22.
36. Troy SM, Mauralidharan G, Micalizzi M, et al. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936) [abstract A-22]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2003:5.
37. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64:63-88.